Investor Alert

April 20, 2021, 9:11 a.m. EDT

Arthritis Pain Management Market : Current Status, In-depth Analysis and Forecast Outlook 2025

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Apr 20, 2021 (Market Insight Reports) -- The global arthritis pain management market is projected to exhibit considerable growth during the forecast period (2019-2025). The high prevalence of this arthritis disorder, the rapid increase in the R&D activities related to the drug development process for the treatment of this disorder by the key players operating is a major factor anticipated to fuel the arthritis pain management market during the forecast period. Johnson & Johnson Services Inc., F. Hoffman La Roche, Merck & Co. Inc., Sanofi SA, Pfizer Inc., Abbvie, Inc., Allergen PLC, Bayer AG, Amgen Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly and Co., Endo Pharmaceutical, Inc., and so on are the key market players operating in the global arthritis pain management industry.

To Request a Sample of our Report on Arthritis Pain Management Market : https://www.omrglobal.com/request-sample/arthritis-pain-management-market

These market players are making a hefty investment in their R&D sector to perform drug development for the launch of new and advanced drugs for the treatment of this disorder. For instance, in February 2020, GlaxoSmithKline Plc received FDA approval fordiclofenac sodium topical gel, 1% (Voltaren Arthritis Pain, GlaxoSmithKline) for temporary relief of arthritis pain. further, in June 2019, Eli Lili & Co. received FDA approval for baricitinib (Olumiant), used to get relief from arthritis pain. Baricitinib is a targeted disease-modifying antirheumatic drug (DMARD) that blocks Janus kinase (JAK), a group of enzymes that enable inflammatory signals to be activated inside a cell.

(Get 15% Discount on Buying this Report)

Browse for Full Report Description at : https://www.omrglobal.com/industry-reports/arthritis-pain-management-market

In June 2017, Regeneron Pharmaceuticals, Inc., and Sanofi S.A. received FDA approval for Kevzara (sarilumab) injection to treat adults with moderate to severe rheumatoid arthritis (RA). Kevzara, a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), may be used as monotherapy or in combination with MTX or other DMARDs. This drug is given to the patient who had an inadequate response or intolerance to methotrexate (MTX-IR) drug. Thus, the increasing FDA approval for the drugs and therapy for the treatment of arthritis is anticipated to be a major factor to drive the growth of the global arthritis pain management market.

Current Market Trends Covered in the Market Report.

  • North America is anticipated to hold a major market share during the forecast period.

  • The rising awareness among people related to the treatment of arthritis including joint replacement

  • Partnerships, collaborations, and new product launches - key drivers of competition in the market.

Global Arthritis Pain Management Market Segmentation

By Drug Type

  • Anti-inflammatory biologics

  • Disease-Modifying Antirheumatic Drugs (DMARDs)

  • Non-steroidal anti-inflammatory drugs (NSAIDs)

  • Corticosteroids

  • Others

By End-User

  • Hospitals

  • Ambulatory Surgical Centres (ASCs)

  • Others

Global Arthritis Pain Management Market Segmentation by region

North America

  • United States

  • Canada


  • UK

  • Germany

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.